​

Galectin Therapeutics Ownership | Who Owns Galectin Therapeutics?

OverviewForecastFinancialsChart

Galectin Therapeutics Ownership Summary

Galectin Therapeutics is owned by 15.78% institutional investors, 30.07% insiders, and 54.16% retail investors. Vanguard group is the largest institutional shareholder, holding 3.56% of GALT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.12% of its assets in Galectin Therapeutics shares.

GALT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockGalectin Therapeutics15.78%30.07%54.16%
SectorHealthcare Stocks 42.64%10.86%46.50%
IndustryBiotech Stocks 45.45%10.77%43.78%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group2.29M3.56%$9.52M
Blackrock1.56M2.52%$3.53M
Advisor group1.22M1.93%$5.24M
Blackrock funding, inc. /de797.67K1.26%$3.38M
Geode capital management633.07K1.00%$2.68M
Marshall wace, llp554.26K0.87%$2.35M
Wealthspire advisors479.52K0.76%$2.03M
Lpl financial360.27K0.57%$1.53M
Commonwealth equity services294.90K0.46%$1.25M
Geneos wealth management243.33K0.38%$1.01M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Retirement guys formula184.56K0.35%$767.78K
Solutions 4 wealth25.38K0.17%$107.47K
Fortis capital advisors106.14K0.07%$441.54K
Sovran advisors225.87K0.06%$711.50K
Vivaldi capital management lp172.44K0.05%$363.86K
Argyle capital partners13.38K0.04%$56.64K
Gsa capital partners llp87.09K0.03%$369.00K
Geneos wealth management243.33K0.02%$1.01M
Traynor capital management101.60K0.02%$422.66K
Belpointe asset management106.14K0.02%$441.54K

Top Buyers

HolderShares% AssetsChange
Blackrock1.56M0.00%851.14K
Marshall wace, llp554.26K0.00%523.86K
Vivaldi capital management lp172.44K0.05%116.81K
Belpointe asset management106.14K0.02%106.14K
Fortis capital advisors106.14K0.07%106.14K

Top Sellers

HolderShares% AssetsChange
Jane street group14.68K--733.98K
Y-intercept (hong kong)---235.19K
Atria wealth solutions---186.00K
Soltis investment advisors---140.75K
Geneos wealth management243.33K0.02%-116.85K

New Positions

HolderShares% AssetsChangeValue
Fortis capital advisors106.14K0.07%106.14K$441.54K
Belpointe asset management106.14K0.02%106.14K$441.54K
Virtu financial38.97K0.01%38.97K$165.00K
Jefferies financial group17.30K0.00%17.30K$73.27M
Two sigma investments, lp16.65K0.00%16.65K$70.50K

Sold Out

HolderChange
Sbi securities-5.00
Legal & general group-38.00
Sterling capital management-74.00
Salem investment counselors-167.00
Point72 (difc)-187.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202587-3.33%10,009,146-4.34%155.76%35-5.41%2618.18%
Jun 30, 202588-7.37%9,965,1580.59%156.42%3624.14%22-26.67%
Mar 31, 202594-14.55%9,893,813-1.83%155.98%30-53.13%29222.22%
Dec 31, 202411023.60%10,078,3233.40%166.61%6464.10%9-50.00%
Sep 30, 20248714.47%9,657,3271.46%156.57%39-11.36%17112.50%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.36M2.12%-29.90K
Vanguard US Total Market Shares ETF1.25M1.97%-
Vanguard Institutional Extnd Mkt Idx Tr543.11K0.85%-173.52K
Fidelity Extended Market Index268.61K0.42%-879.00
Fidelity Small Cap Index142.93K0.23%-17.81K
iShares Russell 2000 Growth ETF103.67K0.16%-
iShares Micro-Cap ETF101.44K0.16%-
BlackRock Extended Equity Market K92.01K0.15%-39.00
Extended Equity Market Fund K89.26K0.14%-1.78K
Fidelity Total Market Index87.23K0.14%-186.00

Recent Insider Transactions

DateNameRoleActivityValue
Feb 06, 2026ELDRED KARY-Buy$810.00
Jan 02, 2026LEWIS JOEL President and CEOSell$77.94K
Jan 05, 2026LEWIS JOEL President and CEOSell$108.34K
Jan 06, 2026LEWIS JOEL President and CEOSell$134.85K
Jan 02, 2026CALLICUTT JACK W Chief Financial OfficerSell$58.39K

Insider Transactions Trends

DateBuySell
2026 Q1-9
2025 Q4239
2025 Q322
2025 Q2--
2025 Q1--

GALT Ownership FAQ

Who Owns Galectin Therapeutics?

Galectin Therapeutics shareholders are primarily institutional investors at 15.78%, followed by 30.07% insiders and 54.15% retail investors. The average institutional ownership in Galectin Therapeutics's industry, Biotech Stocks , is 45.45%, which Galectin Therapeutics falls below.

Who owns the most shares of Galectin Therapeutics?

Galectin Therapeutics’s largest shareholders are Vanguard group (2.29M shares, 3.56%), Blackrock (1.56M shares, 2.52%), and Advisor group (1.22M shares, 1.93%). Together, they hold 8.02% of Galectin Therapeutics’s total shares outstanding.

Does Blackrock own Galectin Therapeutics?

Yes, BlackRock owns 2.52% of Galectin Therapeutics, totaling 1.56M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.53M$. In the last quarter, BlackRock increased its holdings by 851.14K shares, a 119.44% change.

Who is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested?

Retirement guys formula is Galectin Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.35% of its assets in 184.56K Galectin Therapeutics shares, valued at 767.78K$.

Who is the top mutual fund holder of Galectin Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Galectin Therapeutics shares, with 2.12% of its total shares outstanding invested in 1.36M Galectin Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools